{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T10:14:15Z","timestamp":1791281655670,"version":"4.1.0"},"reference-count":58,"publisher":"American Society for Clinical Investigation","issue":"6","license":[{"start":{"date-parts":[[2018,7,23]],"date-time":"2018-07-23T00:00:00Z","timestamp":1532304000000},"content-version":"vor","delay-in-days":123,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"crossref","award":["WT087520"],"award-info":[{"award-number":["WT087520"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,3,22]]},"abstract":"<jats:p>\n                    While the treatment of inflammatory disorders is generally based on inhibiting factors that drive onset of inflammation, these therapies can compromise healing (NSAIDs) or dampen immunity against infections (biologics). In search of new antiinflammatories, efforts have focused on harnessing endogenous pathways that drive resolution of inflammation for therapeutic gain. Identification of specialized pro-resolving mediators (SPMs) (lipoxins, resolvins, protectins, maresins) as effector molecules of resolution has shown promise in this regard. However, their action on inflammatory resolution in humans is unknown. Here, we demonstrate using a model of UV-killed\n                    <jats:italic>Escherichia coli<\/jats:italic>\n                    \u2013triggered skin inflammation that SPMs are biosynthesized at the local site at the start of resolution, coinciding with the expression of receptors that transduce their actions. These include receptors for lipoxin A\n                    <jats:sub>4<\/jats:sub>\n                    (ALX\/FPR2), resolvin E1 (ChemR23), resolvin D2 (GPR18), and resolvin D1 (GPR32) that were differentially expressed on the endothelium and infiltrating leukocytes. Administering SPMs into the inflamed site 4 hours after bacterial injection caused a reduction in PMN numbers over the ensuing 6 hours, the phase of active resolution in this model. These results indicate that in humans, the appearance of SPMs and their receptors is associated with the beginning of inflammatory resolution and that their therapeutic supplementation enhanced the resolution response.\n                  <\/jats:p>","DOI":"10.1172\/jci.insight.94463","type":"journal-article","created":{"date-parts":[[2018,3,21]],"date-time":"2018-03-21T11:01:17Z","timestamp":1521630077000},"source":"Crossref","is-referenced-by-count":70,"title":["Pro-resolving mediators promote resolution in a human skin model of UV-killed Escherichia coli\u2013driven acute inflammation"],"prefix":"10.1172","volume":"3","author":[{"given":"Madhur P.","family":"Motwani","sequence":"first","affiliation":[{"name":"Centre for Clinical Pharmacology and Therapeutics, Division of Medicine, University College London, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain A.","family":"Colas","sequence":"additional","affiliation":[{"name":"Lipid Mediator Unit, Biochemical Pharmacology, William Harvey Research Institute, Bart\u2019s and the London School of Medicine, Queen Mary University of London, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc J.","family":"George","sequence":"additional","affiliation":[{"name":"Centre for Clinical Pharmacology and Therapeutics, Division of Medicine, University College London, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia D.","family":"Flint","sequence":"additional","affiliation":[{"name":"Centre for Clinical Pharmacology and Therapeutics, Division of Medicine, University College London, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6328-3640","authenticated-orcid":true,"given":"Jesmond","family":"Dalli","sequence":"additional","affiliation":[{"name":"Lipid Mediator Unit, Biochemical Pharmacology, William Harvey Research Institute, Bart\u2019s and the London School of Medicine, Queen Mary University of London, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Richard-Loendt","sequence":"additional","affiliation":[{"name":"Division of Neuropathology and, Department of Neurodegenerative Disease, University College London Institute of Neurology, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roel P.H.","family":"De Maeyer","sequence":"additional","affiliation":[{"name":"Centre for Clinical Pharmacology and Therapeutics, Division of Medicine, University College London, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles N.","family":"Serhan","sequence":"additional","affiliation":[{"name":"Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative, and Pain Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek W.","family":"Gilroy","sequence":"additional","affiliation":[{"name":"Centre for Clinical Pharmacology and Therapeutics, Division of Medicine, University College London, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"232","published-online":{"date-parts":[[2018,3,22]]},"reference":[{"issue":"7974","key":"B1","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/S0140-6736(76)93021-X","article-title":"Characterisation of the enzyme defect in chronic granulomatous disease","volume":"1","author":"Segal","year":"1976","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.185.2.207"},{"key":"B3","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1093\/gerona\/glu057","article-title":"Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases","volume":"69 Suppl 1","author":"Franceschi","year":"2014","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0709517"},{"key":"B5","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1007\/s000110050284","article-title":"Anti-inflammatory drugs and their mechanism of action","volume":"47 Suppl 2","author":"Vane","year":"1998","journal-title":"Inflamm Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.52.612.631"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxu102"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2016.39"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1096\/fj.06-7227rev"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.7.4345"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/ni1392"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/ni1182"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.iy.10.040192.001411"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/0167-5699(93)90215-7"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/9550"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0707394104"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nature13479"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1206641109"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-04-496661"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3911"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1402534"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201600144RR"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/cjp2.43"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00024.2014"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0907342107"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20042031"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.021894"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/nri3607"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/ni1276"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20150225"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.112.249508"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1521453113"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.8.1197"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20020760"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M045583"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.plefa.2016.03.004"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s00216-014-8412-5"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200801-061OC"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000002014"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.12.009"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1617290114"},{"key":"B42","doi-asserted-by":"crossref","DOI":"10.1186\/1476-511X-12-89","article-title":"High levels of anti-inflammatory and pro-resolving lipid mediators lipoxins and resolvins and declining docosahexaenoic acid levels in human milk during the first month of lactation","volume":"12","author":"Weiss","year":"2013","journal-title":"Lipids Health Dis"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.plefa.2017.01.004"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201600360R"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.05.010"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002358"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0901037"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0903378"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2011.01731.x"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.114.216036"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.23245"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1501701"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1400313"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1096\/fj.10-159913"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/nature08541"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/nature11042"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0320(20000401)39:4<275::AID-CYTO5>3.0.CO;2-8"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0164978"}],"container-title":["JCI Insight"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/insight.jci.org\/articles\/view\/94463\/files\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T13:03:01Z","timestamp":1779195781000},"score":1,"resource":{"primary":{"URL":"https:\/\/insight.jci.org\/articles\/view\/94463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,22]]},"references-count":58,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,3,22]]},"published-print":{"date-parts":[[2018,3,22]]}},"alternative-id":["10.1172\/jci.insight.94463"],"URL":"https:\/\/doi.org\/10.1172\/jci.insight.94463","relation":{},"ISSN":["2379-3708"],"issn-type":[{"value":"2379-3708","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,22]]},"article-number":"e94463"}}